← Home
Media

Video, interviews & education.

A searchable library of Dr. Mewawalla's public appearances in multiple myeloma and cellular therapy — expert interviews, panel series, educational videos, and podcasts. Every title links to the original publisher.

Videos & Media

Browse the library.

Search or filter by topic, publisher, and year. Two CancerNetwork video series, national oncology-media interviews, educational videos, and podcasts — every title links to the original publisher.

Showing all 32 entries (55 recordings across 2 series and 30 videos).

Evolving Treatment Strategies in Relapsed/Refractory Multiple Myeloma · 14-part CancerNetwork series · Dr. Prerna MewawallaCancerNetwork
CancerNetwork series · Bispecific antibodies · R/R myeloma

Evolving Treatment Strategies in Relapsed/Refractory Multiple Myeloma: Integrating Bispecific Antibodies Into Earlier Lines of Care

A 14-part expert video series on defining anti-CD38–refractory disease, selecting and sequencing BCMA-directed bispecific antibodies and CAR T-cell therapy, interpreting MajesTEC data, and managing safety across patient populations.

Show all 14 episodes ▾Hide episodes ▴
  1. 1.Evolving Treatment Strategies in Relapsed/Refractory Multiple Myeloma: Integrating Bispecific Antibodies Into Earlier Lines of CareWatch on CancerNetwork ↗
  2. 2.Defining Anti-CD38 Refractory Disease in Relapsed/Refractory Multiple MyelomaWatch on CancerNetwork ↗
  3. 3.Treatment Selection Following Anti-CD38 Exposure in Relapsed/Refractory Multiple MyelomaWatch on CancerNetwork ↗
  4. 4.Sequencing CAR T-Cell Therapy and Bispecific Antibodies in Relapsed/Refractory Multiple MyelomaWatch on CancerNetwork ↗
  5. 5.Selecting BCMA-Directed Bispecific Antibodies in Relapsed/Refractory Multiple MyelomaWatch on CancerNetwork ↗
  6. 6.Interpreting Efficacy Endpoints for BCMA-Directed Bispecific Antibodies in Relapsed/Refractory Multiple MyelomaWatch on CancerNetwork ↗
  7. 7.Applying MajesTEC Data Across Patient Populations in Relapsed/Refractory Multiple MyelomaWatch on CancerNetwork ↗
  8. 8.Managing Safety and Infection Risk With Bispecific Antibodies in Relapsed/Refractory Multiple MyelomaWatch on CancerNetwork ↗
  9. 9.Optimizing Dosing Strategies for Bispecific Antibodies in Relapsed/Refractory Multiple MyelomaWatch on CancerNetwork ↗
  10. 10.Choosing Among BCMA-Directed Bispecific Antibodies in Relapsed/Refractory Multiple MyelomaWatch on CancerNetwork ↗
  11. 11.Sequencing CAR T-Cell Therapy and Bispecific Antibodies at First Relapse in Relapsed/Refractory Multiple MyelomaWatch on CancerNetwork ↗
  12. 12.Integrating MajesTEC-9 Data Into Treatment Decisions for Relapsed/Refractory Multiple MyelomaWatch on CancerNetwork ↗
  13. 13.Bispecific Antibodies for Older Patients With Relapsed/Refractory Multiple MyelomaWatch on CancerNetwork ↗
  14. 14.Future Sequencing Strategies for BCMA-Directed Therapies in Relapsed/Refractory Multiple MyelomaWatch on CancerNetwork ↗
Cilta-cel in Multiple Myeloma · Around the Practice CancerNetwork series · Dr. Prerna MewawallaCancerNetworkSeries · ongoing
Around the Practice · CAR T-cell therapy · R/R myeloma

Ciltacabtagene Autoleucel in Multiple Myeloma: Optimizing Sequencing, Safety Management, and Care Team Communication

A CancerNetwork Around the Practice program with Surbhi Sidana, MD, Doris Hansen, MD, and Dr. Mewawalla on where cilta-cel belongs in sequencing and how to individualize CAR T-cell therapy versus bispecific antibodies in relapsed multiple myeloma. New episodes are being added as the series continues.

Show episodes ▾Hide episodes ▴
  1. 1.Where Ciltacabtagene Autoleucel Belongs in SequencingWatch on CancerNetwork ↗
  2. 2.Individualizing CAR T-Cell Therapy vs Bispecific Antibodies in Relapsed Multiple MyelomaWatch on CancerNetwork ↗
  3. 3.Referral Barriers to Chimeric Antigen Receptor T-Cell Therapy in Multiple MyelomaWatch on CancerNetwork ↗
  4. 4.Ciltacabtagene Autoleucel Manufacturing, Debulking, and Bridging in Multiple MyelomaWatch on CancerNetwork ↗
  5. 5.Building Referral Relationships With Community Oncology PracticesWatch on CancerNetwork ↗
  6. 6.Timing Referral, Holding Therapy, and Bridging Therapy DefinitionsWatch on CancerNetwork ↗
  7. 7.Day 28 Discharge and Transition to Shared Community CareWatch on CancerNetwork ↗
  8. 8.Long-Term Monitoring, Prophylaxis, and Vaccination After Cilta-CelWatch on CancerNetwork ↗
  9. 9.Recognizing Delayed Neurotoxicity and Immune Effector Cell EnterocolitisWatch on CancerNetwork ↗
  10. 10.Triaging Post-CAR T Complications in Two Practical ScenariosWatch on CancerNetwork ↗
  11. 11.Practice Changes, Key Takeaways, and Closing RemarksWatch on CancerNetwork ↗
AI in oncology · Dr. Prerna Mewawalla · Managed Healthcare ExecutiveMHE · Feature
AI in oncology · 2026

Community Oncologists Are Turning to AI, but Not All of Them Use Predictive Models

On how community oncology practices are adopting artificial intelligence, and where predictive models still fall short.

Read on Managed Healthcare Executive ↗
AI in oncology · Dr. Prerna Mewawalla · CitelineCiteline · Feature
AI in oncology · 2026

Community Oncologists Use AI, but Reimbursement, Training, Funding, and ROI Stifle Wider Adoption

On the barriers, reimbursement, training, funding, and return on investment, slowing broader AI adoption in community oncology.

Read on Citeline ↗
Access · Dr. Prerna Mewawalla · AHN Med Talks podcastAHN Med Talks · Podcast
Access · Podcast · 2026

Bringing CAR-T and Bispecifics Closer to Home

An AHN Med Talks podcast conversation on delivering CAR T-cell therapy and bispecific antibodies closer to where patients live.

Listen on Apple Podcasts ↗
Professional perspective · Dr. Prerna Mewawalla · Allegheny County Medical SocietyACMS · Feature
Professional perspective · 2026

From Caregiver to Cancer Specialist

An Allegheny County Medical Society profile on how a family diagnosis shaped Dr. Mewawalla's mission to advance blood cancer care.

Read on ACMS ↗
MRD & maintenance · Dr. Prerna Mewawalla · AJMCAJMC · Feature
MRD & maintenance · 2026

MRD Could Decide When Myeloma Maintenance Ends

How measurable residual disease (MRD) status could guide when maintenance therapy can safely be stopped.

Read on AJMC ↗
MRD & maintenance · Dr. Prerna Mewawalla · AJMCAJMC · Feature
MRD & maintenance · 2026

On Rethinking Indefinite Myeloma Maintenance

Why indefinite maintenance may not fit every patient, and how response-adapted approaches could change practice.

Read on AJMC ↗
Professional perspective · Dr. Prerna Mewawalla · AJMCAJMC · Feature
Professional perspective · 2025

Redesigning Trials for Real-World Patient Complexity

A Q&A on designing myeloma trials that reflect the complexity of real-world patients.

Read on AJMC ↗
Relapsed/refractory myeloma · Dr. Prerna Mewawalla · AJMCAJMC · Feature
Relapsed/refractory myeloma · 2026

FDA Approves Novel Iberdomide Regimen in RRMM

Dr. Mewawalla comments on the FDA approval of a new iberdomide-based combination for relapsed/refractory myeloma and what it offers patients who have progressed on prior IMiD therapy.

Read on AJMC ↗
Bispecific antibodies · Dr. Prerna Mewawalla · AJMCAJMC
Bispecific antibodies · 2026

Bispecific Antibodies Are Reshaping Multiple Myeloma Care

How bispecific antibodies are changing myeloma care and how she weighs them against CAR T-cell therapy.

Watch on AJMC ↗
Professional perspective · Dr. Prerna Mewawalla · CURECURE
Professional perspective · 2026

Is a Functional Cure for Multiple Myeloma Within Reach?

An expert roundtable, featuring Dr. Mewawalla, on whether a functional cure for myeloma is now achievable.

Watch on CURE ↗
CAR T-cell therapy · Dr. Prerna Mewawalla · OncoDailyOncoDaily · Feature
CAR T-cell therapy · 2025

Advances in CAR-T Therapies for Multiple Myeloma at the ICE-T Congress

A featured recap of her ICE-T Congress presentation on advances in CAR T-cell therapy for myeloma.

Read on OncoDaily ↗
Relapsed/refractory myeloma · Dr. Prerna Mewawalla · VuMediVuMedi
Relapsed/refractory myeloma · 2025

TANDEM 2025: Sequencing BCMA-Directed Therapies

Real-world outcomes and insights on sequential treatment with BCMA-directed therapies.

Watch on VuMedi ↗
Professional perspective · Dr. Prerna Mewawalla · AJMCAJMC
Professional perspective

A Personal Mission: On Myeloma's Transformation

How a family diagnosis shaped a career, and how far treatment has come.

Watch on AJMC ↗
CAR T-cell therapy · Dr. Prerna Mewawalla · OncLiveOncLive
CAR T-cell therapy

Real-World Roles of Cilta-Cel and Ide-Cel in R/R Myeloma

How earlier-line CAR T-cell therapy approvals are shifting the paradigm.

Watch on OncLive ↗
CAR T-cell therapy · Dr. Prerna Mewawalla · OncLiveOncLive
CAR T-cell therapy · also on CGTLive

Unmet Needs After Early CAR T-cell Therapy in R/R Myeloma

What still needs solving after earlier-line cellular therapy. Same recording, published on two outlets.

Watch on OncLive ↗ · Also on CGTLive ↗
Bispecific antibodies · Dr. Prerna Mewawalla · OncoDailyOncoDaily · Feature
Bispecific antibodies

The Evolving Role of FcRH5-Targeted Therapy

The potential of cevostamab and FcRH5-directed treatment.

Read on OncoDaily ↗
Bispecific antibodies · Dr. Prerna Mewawalla · CancerNetworkCancerNetwork
Bispecific antibodies

Cevostamab May Fill a Gap in the Armamentarium

Where a novel bispecific could fit among today's options.

Watch on CancerNetwork ↗
Access and delivery · Dr. Prerna Mewawalla · CancerNetworkCancerNetwork
Access

Therapy Is Only as Good as Its Access

Why equitable access is central to real-world outcomes.

Watch on CancerNetwork ↗
Bispecific antibodies · Dr. Prerna Mewawalla · CancerNetworkCancerNetwork
Bispecific antibodies · Access

Moving Bispecifics and Prophylaxis to Outpatient Multiple Myeloma Care

Shifting bispecific-antibody administration and prophylaxis into the outpatient setting.

Watch on CancerNetwork ↗
Toxicity management · Dr. Prerna Mewawalla · CancerNetworkCancerNetwork
Toxicity management

How Does One Manage Talquetamab's Unique AE Profile in Multiple Myeloma?

Recognizing and managing talquetamab's distinctive adverse-event profile.

Watch on CancerNetwork ↗
Toxicity management · Dr. Prerna Mewawalla · CancerNetworkCancerNetwork
Toxicity management

Managing BCMA/GPRC5D-Associated CRS and ICANS in the Real-World Setting

Practical, real-world management of CRS and ICANS with BCMA- and GPRC5D-directed therapies.

Watch on CancerNetwork ↗
Toxicity management · Dr. Prerna Mewawalla · CancerNetworkCancerNetwork
Toxicity management

Managing Toxicities in BCMA/GPRC5D-Directed Therapies in Multiple Myeloma

An overview of toxicity management across BCMA- and GPRC5D-directed therapies.

Watch on CancerNetwork ↗
Professional perspective · Dr. Prerna Mewawalla · Targeted OncologyTargeted Oncology
Professional perspective

An Explosion of Agents for Myeloma Treatment

On the rapid expansion of treatment options now available in multiple myeloma.

Watch on Targeted Oncology ↗
Relapsed/refractory myeloma · Dr. Prerna Mewawalla · Targeted OncologyTargeted Oncology
Relapsed/refractory myeloma

Key Factors for Therapy Choice in Relapsed/Refractory Multiple Myeloma

The factors that guide treatment selection at relapse.

Watch on Targeted Oncology ↗
Newly diagnosed myeloma · Dr. Prerna Mewawalla · Targeted OncologyTargeted Oncology
Newly diagnosed myeloma

Recent Trials Change Practice for Newly Diagnosed Multiple Myeloma

How recent trial data are reshaping frontline treatment.

Watch on Targeted Oncology ↗
Toxicity management · Dr. Prerna Mewawalla · VuMediVuMedi
Toxicity management

CRS & ICANS: A Practical Guide

Recognition, grading, and management of CRS and ICANS with immune effector cell therapies.

Watch on VuMedi ↗
Bispecific antibodies · Dr. Prerna Mewawalla · VuMediVuMedi
Bispecific antibodies · Access

Myeloma Bispecifics in Practice

Efficacy, safety, and bringing care closer to home with available and emerging bispecific antibodies.

Watch on VuMedi ↗
Bispecific antibodies · Dr. Prerna Mewawalla · VuMediVuMedi
Bispecific antibodies · Access

Administering Bispecifics in Outpatient & Community Settings

Practical guidance for delivering bispecific antibody therapy safely outside academic centers.

Watch on VuMedi ↗
Newly diagnosed myeloma · Dr. Prerna Mewawalla · VuMediVuMedi
Newly diagnosed myeloma

Trials Integrating BCMA Bispecifics in NDMM

Bringing BCMA-directed bispecifics into newly diagnosed multiple myeloma.

Watch on VuMedi ↗
Relapsed/refractory myeloma · Dr. Prerna Mewawalla · VuMediVuMedi
Relapsed/refractory myeloma

Selinexor in R/R MM

Key trial data, use in high-risk disease, CAR T-cell therapy bridging, and side-effect management.

Watch on VuMedi ↗

No videos match your search and filters.